In its largest sin­gle-as­set pur­chase ever, Take­da snaps up TYK2 drug for $4B up­front

Take­da is buy­ing Nim­bus’ late-stage TYK2 in­hibitor, an oral drug for au­toim­mune dis­eases, for $4 bil­lion in cash up­front. That sets Take­da up to com­pete with Bris­tol My­ers Squibb, which got the first TYK2 in­hibitor ap­proval in Sep­tem­ber for pso­ri­a­sis.

The Nim­bus/Take­da deal is among the in­dus­try’s largest sin­gle-as­set pur­chas­es dat­ing back to 2008, af­ter Am­gen bought Ote­zla from Cel­gene in 2019 ($13.4 bil­lion to­tal), ac­cord­ing to Chris Doko­ma­ji­lar at Deal­For­ma. Nim­bus can get an­oth­er po­ten­tial $2 bil­lion if the drug, once on the mar­ket, reach­es sales mile­stones — $1 bil­lion for reach­ing an­nu­al net sales of $4 bil­lion and an­oth­er bil­lion for net sales of $5 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER